Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs.

Alumis Announces Pricing of Initial Public Offering Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering